María del Carmen Durand-Vásquez

María del Carmen Durand-Vásquez

Auto-generated profile, based on publicly available information

María del Carmen Durand-Vásquez

Division of Non-communicable diseases, Endocrinology research line, Hospital de Apoyo Chepén, Chepén, Perú

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2023 in Expert Review of Endocrinology & Metabolism
Verified
Journal Article
Closed access
MCMarcio José Concepción-Zavaleta
Marcio José Concepción-Zavaleta
JCJulia Cristina Coronado-Arroyo
Julia Cristina Coronado-Arroyo
JQJuan Eduardo Quiroz-Aldave
Juan Eduardo Quiroz-Aldave
MDMaría del Carmen Durand-Vásquez
María del Carmen Durand-Vásquez
SISofía Pilar Ildefonso-Najarro
Sofía Pilar Ildefonso-Najarro
JPJosé Paz-Ibarra
José Paz-Ibarra
Infertility is defined as the inability to conceive after unprotected sexual intercourse for at least 12 consecutive months. Our objective is to present an updated narrative review on the endocrine causes of infertility in women. A comprehensive review was conducted using Scielo, Scopus, and EMBASE databases, comprising 245 articles. The pathophysiology of infertility in women was described, including endocrinopathies such as hypothalamic amenorrhea, hyperprolactinemia, polycystic ovary syndrome, primary ovarian insufficiency, obesity, thyroid dysfunction, and adrenal disorders. The diagnostic approach was outlined, emphasizing the necessity of hormonal studies and ovarian response assessments. Additionally, the treatment plan was presented, commencing with non-pharmacological interventions, encompassing the adoption of a Mediterranean diet, vitamin supplementation, moderate exercise, and maintaining a healthy weight. Subsequently, pharmacological treatment was discussed, focusing on the management of associated endocrine disorders and ovulatory dysfunction. This comprehensive review highlights the impact of endocrine disorders on fertility in women, providing diagnostic and therapeutic algorithms. Despite remaining knowledge gaps that hinder more effective treatments, ongoing research and advancements show promise for improved fertility success rates within the next five years. Enhanced comprehension of the pathophysiology behind endocrine causes and the progress in genetic research will facilitate the delivery of personalized treatments, thus enhancing fertility rates.

19 September 2023 in World Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
MCMarcio José Concepción-Zavaleta
Marcio José Concepción-Zavaleta
JQJuan Eduardo Quiroz-Aldave
Juan Eduardo Quiroz-Aldave
MDMaría del Carmen Durand-Vásquez
María del Carmen Durand-Vásquez
EGElman Rolando Gamarra-Osorio
Elman Rolando Gamarra-Osorio
JCJuan del Carmen Valencia de la Cruz
Juan del Carmen Valencia de la Cruz
JPJosé Paz-Ibarra
José Paz-Ibarra

1 December 2023 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
JQJuan Eduardo Quiroz-Aldave
Juan Eduardo Quiroz-Aldave
MDMaría Del Carmen Durand-Vásquez
María Del Carmen Durand-Vásquez
FCFreddy Shanner Chávez-Vásquez
Freddy Shanner Chávez-Vásquez
ARAlexandra Noelia Rodríguez-Angulo
Alexandra Noelia Rodríguez-Angulo
SGSonia Elizabeth Gonzáles-Saldaña
Sonia Elizabeth Gonzáles-Saldaña
MCMarcio José Concepción-Zavaleta
Marcio José Concepción-Zavaleta
Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of various neoplasms. Its main adverse effects include renal damage. A comprehensive review was conducted, including 100 articles from the Scielo, Scopus, and EMBASE databases. Ifosfamide-induced nephrotoxicity is attributed to its toxic metabolites, such as acrolein and chloroacetaldehyde, which cause mitochondrial damage and oxidative stress in renal tubular cells. Literature review found a 29-year average age with no gender predominance and a mortality of 13%. Currently, no fully effective strategy exists for preventing ifosfamide-induced nephrotoxicity; however, hydration, forced diuresis, and other interventions are employed to limit renal damage. Long-term renal function monitoring is essential for patients treated with ifosfamide. Ifosfamide remains essential in neoplasm treatment, but nephrotoxicity, often compounded by coadministered drugs, poses diagnostic challenges. Preventive strategies are lacking, necessitating further research. Identifying timely risk factors can mitigate renal damage, and a multidisciplinary approach manages established nephrotoxicity. Emerging therapies may reduce ifosfamide induced nephrotoxicity.

30 June 2023 in Annals of Pediatric Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MCMarcio José Concepción-Zavaleta
Marcio José Concepción-Zavaleta
CACristian David Armas
Cristian David Armas
JQJuan Eduardo Quiroz-Aldave
Juan Eduardo Quiroz-Aldave
EGEilhart Jorge García-Villasante
Eilhart Jorge García-Villasante
AGAna Cecilia Gariza-Solano
Ana Cecilia Gariza-Solano
FZFrancisca Elena Zavaleta-Gutiérrez
Francisca Elena Zavaleta-Gutiérrez
Cushing disease (CD) is the main cause of endogenous Cushing syndrome (CS) and is produced by an adrenocorticotropic hormone (ACTH)-producing pituitary adenoma. Its relevance in pediatrics is due to the retardation of both growth and developmental processes because of hypercortisolism. In childhood, the main features of CS are facial changes, rapid or exaggerated weight gain, hirsutism, virilization, and acne. Endogenous hypercortisolism should be established after exogenous CS has been ruled out based on 24-hour urinary free cortisol, midnight serum or salivary cortisol, and dexamethasone suppression test; after that, ACTH dependence should be established. The diagnosis should be confirmed by pathology. The goal of treatment is to normalize cortisol level and reverse the signs and symptoms. Treatment options include surgery, medication, radiotherapy, or combined therapy. CD represents a challenge for physicians owing to its multiple associated conditions involving growth and pubertal development; thus, it is important to achieve an early diagnosis and treatment in order to control hypercortisolism and improve the prognosis. Its rarity in pediatric patients has led physicians to have limited experience in its management. The objective of this narrative review is to summarize the current knowledge about the pathophysiology, diagnosis, and treatment of CD in the pediatric population.

13 September 2023 in Endocrine Practice
Verified
Journal Article
Closed access
JQJuan Eduardo Quiroz-Aldave
Juan Eduardo Quiroz-Aldave
MCMarcio José Concepción-Zavaleta
Marcio José Concepción-Zavaleta
MDMaría del Carmen Durand-Vásquez
María del Carmen Durand-Vásquez
LCLuis Alberto Concepción-Urteaga
Luis Alberto Concepción-Urteaga
EGElman Rolando Gamarra-Osorio
Elman Rolando Gamarra-Osorio
ARAlejandro Román-González
Alejandro Román-González

23 January 2024 in Expert Review of Endocrinology & Metabolism
Verified
Journal Article
Closed access
JQJuan Eduardo Quiroz-Aldave
Juan Eduardo Quiroz-Aldave
MDMaría Del Carmen Durand-Vásquez
María Del Carmen Durand-Vásquez
EGElman Rolando Gamarra-Osorio
Elman Rolando Gamarra-Osorio
LCLuis Alberto Concepción-Urteaga
Luis Alberto Concepción-Urteaga
SPSamuel Pecho Pecho-Silva
Samuel Pecho Pecho-Silva
MCMarcio José Concepción-Zavaleta
Marcio José Concepción-Zavaleta
Introduction: Adverse reactions to tuberculosis treatment can impact patient adherence and prognosis. Hypothyroidism is a frequent adverse reaction caused using ethionamide, prothionamide, and para-aminosalicylic acid and is often underdiagnosed.Areas covered: We searched Scielo, Scopus, and EMBASE databases, including 67 articles. Antitubercular drug-induced hypothyroidism has a prevalence of 17%. It occurs after 2 to 3 months of treatment and resolves within 4 to 6 weeks after discontinuation. It is postulated to result from the inhibition of thyroperoxidase function, blocking thyroid hormone synthesis. Symptoms are nonspecific, necessitating individualized thyroid-stimulating hormone measurement for detection. Specific guidelines for management are lacking, but initiation of treatment with levothyroxine, as is customary for primary hypothyroidism, is recommended. Discontinuation of antitubercular drugs is discouraged, as it may lead to unfavorable consequences.Expert opinion: Antitubercular drug-induced hypothyroidism is more common than previously thought, affecting one in six MDR-TB patients. Despite diagnostic and treatment recommendations, implementation is hindered in low-income countries due to the lack of certified laboratories. New drugs for tuberculosis treatment may affect thyroid function, requiring vigilant monitoring for complications, including hypothyroidism.